InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Sunday. The firm set a “sell” rating on the stock.

InspireMD Stock Down 10.4 %

Shares of NSPR stock opened at $2.32 on Friday. InspireMD has a twelve month low of $1.87 and a twelve month high of $3.80. The company has a market cap of $71.07 million, a P/E ratio of -3.09 and a beta of 0.74. The business has a fifty day simple moving average of $2.78 and a 200 day simple moving average of $2.74.

Hedge Funds Weigh In On InspireMD

Several large investors have recently bought and sold shares of NSPR. Affiance Financial LLC raised its position in InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock valued at $497,000 after purchasing an additional 5,376 shares during the last quarter. Legato Capital Management LLC bought a new position in InspireMD in the fourth quarter valued at about $47,000. Essex Investment Management Co. LLC bought a new position in InspireMD in the fourth quarter valued at about $191,000. Renaissance Technologies LLC bought a new position in InspireMD in the fourth quarter valued at about $27,000. Finally, Northern Trust Corp raised its position in InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after purchasing an additional 24,452 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.